Working… Menu
Trial record 53 of 55 for:    hki-272 OR neratinib

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02977780
Recruitment Status : Recruiting
First Posted : November 30, 2016
Last Update Posted : August 27, 2019
Eli Lilly and Company
Puma Biotechnology, Inc.
Accelerate Brain Cancer Cure
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : May 2021